Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Diagnostic usefulness of subgenomic RNA detection of viable SARS-CoV-2 in patients with COVID-19

Ji Yeun Kim¹,¹, Joon-Yong Bae ³,¹, Seongman Bae ¹,¹, Hye Hee Cha ¹, Ji-Soo Kwon ¹, Mi Hyun Suh ¹, Hyun Jung Lee ¹, Jiwon Jung ¹, Min Jae Kim ¹, Chunguang Cui ³, Heedo Park ²,³, Jungmin Lee ³, Man-Seong Park ²,³, Sung-Han Kim ¹,⁴

¹) Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
²) BK21 Graduate Program, Department of Biomedical Sciences, Korea University College of Medicine, Seoul, 02841, Republic of Korea
³) Department of Microbiology, Institute for Viral Diseases, Biosafety Center, College of Medicine, Korea University, Seoul, South Korea

Introduction

Diagnosis of COVID-19 has relied on detection of SARS-CoV-2 viral RNA by real-time reverse transcription PCR (RT-PCR). This method is rapid and highly sensitive, but the viral RNA may be detectable for many weeks after clinical recovery [1,2], which could unnecessarily prolong patients’ isolation. In addition, we do not know, on a real-time basis, the viability of SARS-CoV-2 in patients confirmed by conventional RT-PCR of SARS-CoV-2, so some unnecessary contact tracing with quarantine is inevitable. Therefore, the development of a rapid diagnostic test for viable SARS-CoV-2 is important for conserving resources, and compliance with quarantine and isolation policies.
Culture-based isolation of SARS-CoV-2 virus is the best indicator of the presence of replicating virus, but it is difficult, labour-intensive and time-consuming. In addition, it is further complicated by the need for Biosafety Level 3 facilities. Meanwhile, coronaviruses have a unique mechanism of discontinuous transcription involving the synthesis of subgenomic RNA [3]. Coronavirus subgenomic RNAs contain a nested set of negative-sense RNAs from the 3′ end of the virus genome joined to a common leader sequence of about 70 nucleotides derived from the 5′ end of the genomic RNA [4,5]. Therefore, the detection of subgenomic RNAs may better reflect replication-competent virus than detection of conventional genomic RNA [6]. However, there have been limited studies with regard to the correlation between replicative SARS-CoV-2 and subgenomic RNAs in respiratory samples [6–8]. We had a good opportunity to study COVID-19 patients of various severities including immunocompromised patients who were expected to shed viable virus for a prolonged period. We therefore evaluated the utility of subgenomic RNAs for diagnosing viable SARS-CoV-2 in patients with COVID-19.

Materials and methods

Patients and specimens

Respiratory specimens were collected from patients with confirmed COVID-19 who agreed to multiple serial sampling and were admitted to Asan Medical Center, a 2700-bed tertiary hospital in Seoul, Republic of Korea, between February 2020 and December 2020. Diagnosis of COVID-19 was confirmed with nasopharyngeal (NP) swab samples by RT-PCR for the RdRp, N and E genes of SARS-CoV-2 using the Alphalplex™ 2019-nCoV assay (Seegene, Seoul, Republic of Korea) or a PowerChek 2019-nCoV real-time PCR kit (Kogene Biotech, Seoul, Republic of Korea). NP swab samples, sputum and saliva samples were collected from the patients between the initial day of admission and the day of discharge, up to 50 days after symptom onset. NP swab samples in viral transport medium, and sputum and saliva samples collected in an airtight container, were aliquoted and stored in −80 °C deep freeze until use. This study was reviewed and approved by the ethics committee of the institutional review board of Asan Medical Center (IRB No. 2020-0297), and all participants gave written informed consent.

Measurement of viral load by real-time RT-PCR assay

The collected respiratory samples were inactivated at 65 °C for 30 min in a special negative pressure laboratory. Viral RNA was extracted from the respiratory specimens using a QIAamp viral RNA Mini kit (Qiagen Inc., Hilden, Germany). To determine the SARS-CoV-2 viral RNA copy number, multiplex real-time RT-PCR assays targeting the S and N genes were developed; primer and probe sequences and detailed procedures are provided Table S1.

Detection of N and S gene subgenomic RNAs

SARS-CoV-2 N and S gene subgenomic RNAs were detected with RocketScript RT-PCR Premix (Bioneer Co. Daejeon, Republic of Korea). The shared forward primer was designed in the 5′ leader sequence, and reverse primers were located in the gene sequences coding for protein N and S (Table S2). RT-PCR reactions were performed as described in the supplementary materials.

Isolation of SARS-CoV-2 from specimen

Culture-based isolation of SARS-CoV-2 from respiratory specimens was performed by a plaque assay in a Biosafety Level 3 laboratory at Korea University College of Medicine, Seoul, Republic of Korea. Detailed procedures are described in the supplementary material.

Statistical analyses

Categorical variables were compared using Fisher’s exact test, and continuous variables with the Mann–Whitney U-test, as appropriate. The diagnostic performance for each test was calculated and compared by using logistic regression with generalized estimating equation to account for the clustering effects. All tests of significance were 2-tailed; p ≤ 0.05 were considered statistically significant. IBM SPSS Statistics for Windows, version 23.0 (IBM Corp., Armonk, NY, USA) was used for these statistical analyses.

Results

Clinical characteristics of patients

Twenty confirmed COVID-19 patients were included in this study, and the clinical characteristics of these patients are presented in Table 1. The symptoms of the patients were classified according to the NIH classification into four mild, for moderate and 12 severe and critical. Two patients with acute leukaemia and one patient with lymphoma were included among the 20 patients. Detailed clinical characteristics of the individuals are shown in Fig. S2.

Table 1

| Table 1 | Clinical characteristics of patients in this study |
|------------------------|--------------------------------------------------|
| Age, year | 60 (50–66) |
| Male | 9 (45) |
| Underlying disease | |
| Diabetes | 4 (20) |
| Hypertension | 6 (30) |
| Cardiovascular disease | 3 (15) |
| Chronic kidney disease | 0 (0) |
| Chronic lung disease | 5 (25) |
| Chronic liver disease | 1 (5) |
| Solid tumour | 1 (5) |
| Haematological malignancy | 3 (15) |
| Rheumatic disease | 0 (0) |
| Obesity (body mass index >25) | 1 (5) |
| Initial symptom | |
| Fever | 18 (90) |
| Chills or rigors | 3 (15) |
| Myalgia | 5 (25) |
| Headache | 2 (10) |
| Sore throat | 2 (10) |
| Nausea or vomiting | 3 (15) |
| Diarrhoea | 0 (0) |
| Fatigue | 3 (15) |
| Congestion or runny nose | 1 (5) |
| Cough | 9 (45) |
| Shortness of breathing | 3 (15) |
| Difficulty of breathing | 4 (20) |
| New olfactory disorder | 2 (10) |
| New taste disorder | 2 (10) |
| Hospital course | |
| Pneumonia | 16 (80) |
| Supplemental oxygen therapy | 11 (55) |
| Mechanical ventilation | 4 (20) |
| Extracorporeal membrane oxygenation | 1 (5) |
| In-hospital mortality | 2 (10) |
| Length of hospital stay | 29 (18–38) |
| Prolonged hospitalization (>14 days) | 15 (75) |
| Reason for prolonged hospitalization | |
| Severe COVID-19 | 10 (50) |
| Underlying medical condition | 3 (15) |
| Isolation until negative conversion of viral RNA | 2 (10) |

Data are expressed as the number (%) of patients or median (interquartile range).
Viral loads, subgenomic RNA, and isolation of SARS-CoV-2 by culture

A total 189 respiratory specimens from the twenty COVID-19-confirmed patients were analysed. There were 74 nasopharyngeal swab specimens, 62 sputum specimens and 53 saliva specimens, and the collection times ranged from 1 to 49 days after symptom onset. The N and S genes were detected by genomic RNA RT-PCR assays (limits of detection: 2.6 log copies/mL of specimen) in 160 (N gene) and 161 (S gene) of the 189 specimens. Subgenomic RNA was detected in 108 (N gene) and 107 (S gene) specimens, and viral loads in the positive subgenomic RNA-specimens were 6.21 ± 1.32 log copies/mL and the viral loads in the negative subgenomic RNA specimens 3.35 ± 0.67 log copies/mL (p < 0.001, Mann–Whitney U-test). Sixty-two specimens were successfully cultured and viral loads were 6.76 ± 0.56 log copies/mL in positive subgenomic RNA; thus the specificities of genomic and subgenomic RNA for culture negative specimens were 23% (95% CI 14–34%) and 65% (95% CI 53–75%), respectively (p < 0.001). For the S gene, the specificities for genomic and subgenomic RNAs among the culture negatives were 17% (16/93, 95% CI 11–26%) and 68% (95% CI 56–78%), respectively (p < 0.001). Depending on the sample site, NP swab samples showed the highest specificity of subgenomic RNA, 69% (N gene, 22/32, 95% CI 54–80%) and 72% (S gene, 23/32, 95% CI 57–83%), and saliva samples showed the lowest specificity of subgenomic RNA, 54% (N gene, 13/24, 95% CI 41–67%) and 58% (S gene, 14/24, 95% CI 44–71%). (Table 2).

This study included three patients with immunocompromised conditions. The sensitivity and specificity of genomic and subgenomic RNA in patients with or without immunocompromised condition are presented in Table S3. In the non-immunocompromised patients, the sensitivity and specificity of subgenomic RNA detection were comparable with that in total patients (sensitivity of N and S gene, 100% (42/42), 90–100%; specificity of N gene, 66 (55/83), 54–77%; specificity of S gene, 69% (57/83), 56–79%).

The distributions of positive subgenomic RNA and culture test results as a function of number of days after symptom onset are shown in Fig. 2 and Table 3. The mean durations of positive culture and subgenomic RNA were 11.39 ± 10.34 and 13.75 ± 11.22 days after symptom onset, respectively (p 0.437, Mann–Whitney U-

![Fig. 1. Plot of subgenomic RNA results stratified by SARS-CoV-2 viral gene copy number (log copies/mL), and culture-isolation results for patients with COVID-19. (A) N gene; (B) S gene; red dot, positive subgenomic RNA; green dot, negative subgenomic RNA.](image)

**Table 2**

Predictive performances of genomic and subgenomic RNA detection forculturable virus

| Sample | Genomic RNA detection | Subgenomic RNA detection |
|--------|-----------------------|--------------------------|
|        | N gene | S Gene | N gene | S Gene |
| Sensitivity % (n/Na, 95% CI) | All 100 (62/62, 91–100) | 100 (62/62, 93–100) | 100 (62/62, 93–100) | 100 (62/62, 93–100) |
|       | NP swab 100 (31/31, 86–100) | 100 (31/31, 86–100) | 100 (31/31, 86–100) | 100 (31/31, 86–100) |
|       | Sputum 100 (18/18, 78–100) | 100 (18/18, 78–100) | 100 (18/18, 78–100) | 100 (18/18, 78–100) |
|       | Saliva 100 (13/13, 72–100) | 100 (13/13, 72–100) | 100 (13/13, 72–100) | 100 (13/13, 72–100) |
| Specificity % (n/Nb, 95% CI) | All 23 (21/93, 14–34) | 17 (16/93, 11–26) | 65 (60/93, 53–75) | 68 (63/93, 56–78) |
|       | NP swab 25 (8/32, 14–40) | 6 (2/32, 2–18) | 90 (22/24, 54–80) | 72 (23/32, 57–83) |
|       | Sputum 24 (9/37, 16–36) | 22 (8/37, 12–35) | 68 (25/37, 50–81) | 70 (26/37, 53–83) |
|       | Saliva 17 (4/24, 8–31) | 25 (6/24, 11–47) | 54 (13/24, 41–67) | 58 (14/24, 44–71) |
| Positive predictive value % (95% CI) | All 46 (33–60) | 45 (31–59) | 65 (51–77) | 67 (53–79) |
|       | NP swab 56 (42–60) | 51 (36–66) | 76 (60–87) | 78 (61–88) |
|       | Sputum 39 (25–56) | 38 (24–55) | 60 (42–76) | 62 (43–78) |
|       | Saliva 39 (20–62) | 42 (21–66) | 54 (31–76) | 57 (33–78) |
| Negative predictive value % (95% CI) | All 100 (81–100) | 100 (76–100) | 100 (93–100) | 100 (93–100) |
|       | NP swab 100 (60–100) | 100 (20–100) | 100 (82–100) | 100 (82–100) |
|       | Sputum 100 (63–100) | 100 (60–100) | 100 (83–100) | 100 (84–100) |
|       | Saliva 100 (40–100) | 100 (52–100) | 100 (72–100) | 100 (73–100) |

1n/N, test positive n/culture positive N.
2n/N, test negative n/culture negative N.
the immune system is intact, viral shedding occurs earlier and is of shorter duration in patients with severe disease [9,11]. Van Kampen et al. detected culturable virus up to 10 days 11 days after symptom onset (p < 0.001 between viral culture and genomic RNA detection, Mann–Whitney U-test). Excluding the three of immunocompromised patients, the mean durations of positive culture, subgenomic RNA and genomic RNA were 8.47 ± 3.93, 10.65 ± 5.70 and 20.35 ± 8.44. (between culture and subgenomic RNA, p 0.342; between culture and genomic RNA, p < 0.001). The results for all 189 specimens including contaminated or cell detached samples by cell culture as a function of days after symptom onset are shown in Table S4.

SARS-CoV-2 virus was cultured from 23 of 25 specimens with viral loads ≥7.0 log copies/mL, 19 of 32 specimens with viral loads of 6.0–6.99 log copies/mL, 17 of 38 specimens with viral loads of 5.0–5.99 log copies/mL, three of 26 specimens with viral loads of 4.0–4.99 log copies/mL and none of 50 specimens with viral loads of <4.0 log copies/mL based on copy number of S gene (Table S5). The corresponding data for subgenomic RNAs were detected from 23 of 25 specimens with viral loads ≥7.0 log copies/mL, 28 of 32 specimens with viral loads 6.0–6.99 log copies/mL, 30 of 38 specimens with viral loads 5.0–5.99 log copies/mL, nine of 26 specimens with viral loads 4.0–4.99 log and two of 29 specimens with viral loads 3.0–3.99 log copies/mL, none of 39 specimens with viral loads <3.0 log copies/mL based on copy number of the S gene are also presented in Table S5.

Discussion

The idea of subgenomic RNA detection is not novel. Two studies have reported that replicative virus determined by viral culture and subgenomic RNA detection was not found beyond 8 or 9 days after symptom onset in patients with mild illness [6,7]. However, viral shedding has been observed for longer in patients with severe disease [9–11]. Van Kampen et al. detected culturable virus up to 20 days after symptom onset in patients with moderate-to-severe disease [12]. We extensively investigated whether the subgenomic RNA detect can reflect the viable virus by using various respiratory samples from patients with various severity of illness.

The strength of our study is that we compared the positive rate of subgenomic RNA detection with other tests according to the duration of symptoms in patients with severe SARS-CoV-2 infection or immunocompromised patients with SARS-CoV-2 infection as well as in patients with non-severe SARS-CoV-2 infection. The sensitivity and specificity of virus culture as a surrogate for the transmissibility of SARS-CoV-2 is not perfect. So, the several samples including positive subgenomic RNA but the failed cell culture due to cell detachment or contamination may be likely to have viable SARS-CoV-2 especially from respiratory samples of patients at the earliest period from the symptom onset. Taken together, our study results indicate that the assay for subgenomic RNA predicts the duration of infective viral shedding accurately, as its duration was similar to that of culturable virus and its highest positive rate at the earliest period from the symptom onset.

Most of specimens with viral loads ≥6.0 log copies/mL were positive for both culture and subgenomic RNA, but numerous specimens with viral loads of 4.0–5.99 were classified as culture-negative and subgenomic RNA-positive. Two possible explanations for this are that (a) viral culture may not be sensitive enough to detect small amounts of viable virus or (b) subgenomic RNAs can still be detected in the absence of viable SARS-CoV-2. Indeed, 34 of 189 specimens (18%) resulted in culture failure due to bacterial contamination or cell detachment. In addition, 36 of 95 the specimens (38%) with high viral loads (>5 log copies/mL) resulted in culture-negative (Table S5). Although, in the cell culture system we used, viable virus could still be detected in dilutions containing only 1 PFU/mL [13], some invalid culture result could not rule out the possibility that some viable virus might only be detected by subgenomic RNA PCR. However, subgenomic SARS-CoV-2 RNA tightly associated with membrane structures might be protected from cellular RNases, so the detection of subgenomic RNAs from infected patients may not always be indicative of viable virus [8]. In addition, the previous study on the comparison of levels of viral subgenomic RNAs to viral genomic RNAs in the same sample

Table 3

Comparison of tests for Genomic RNA and Subgenomic RNA, and culture results as a function of days after symptom onset

| Assay     | Days after symptom onset | No. Positive/no. Tested (%) |
|-----------|--------------------------|----------------------------|
|           | 1–5 days                 |                            |
| Genomic RNA | N gene                  | 35/35 (100)                |
|           | S gene                   | 35/35 (100)                |
| Subgenomic RNA | N gene                | 33/35 (94)                 |
|           | S gene                   | 33/35 (94)                 |
| Culture   |                          | 28/35 (80)                 |
|           | 6–10 days                |                            |
| Genomic RNA | N gene                  | 20/23 (87)                 |
|           | S gene                   | 23/23 (100)                |
| Subgenomic RNA | N gene                | 11/23 (48)                 |
|           | S gene                   | 11/23 (48)                 |
| Culture   |                          | 4/23 (17)                  |
|           | 11–15 days               |                            |
| Genomic RNA | N gene                  | 6/17 (35)                  |
|           | S gene                   | 11/17 (65)                 |
| Subgenomic RNA | N gene                | 10/24 (42)                 |
|           | S gene                   | 10/24 (42)                 |
| Culture   |                          | 0/17 (0)                   |
|           | 16–20 days               |                            |
| Genomic RNA | N gene                  | 6/8 (75)                   |
|           | S gene                   | 5/8 (63)                   |
| Subgenomic RNA | N gene                | 1/17 (6)                   |
|           | S gene                   | 1/17 (6)                   |
| Culture   |                          | 2/8 (25)                   |
|           | 21–30 days               |                            |
| Genomic RNA | N gene                  | 3/4 (75)                   |
|           | S gene                   | 3/4 (75)                   |
| Subgenomic RNA | N gene                | 2/4 (50)                   |
|           | S gene                   | 2/4 (50)                   |
| Culture   |                          | 1/2 (50)                   |
|           | 31–40 days               |                            |
| Genomic RNA | N gene                  | 1/3 (33)                   |
|           | S gene                   | 1/3 (33)                   |
| Subgenomic RNA | N gene                | 1/3 (33)                   |
|           | S gene                   | 1/3 (33)                   |
| Culture   |                          | 0/3 (0)                    |
|           | 41–50 days               |                            |
| Genomic RNA | N gene                  | 0/3 (0)                    |
|           | S gene                   | 0/3 (0)                    |
| Subgenomic RNA | N gene                | 0/3 (0)                    |
|           | S gene                   | 0/3 (0)                    |
| Culture   |                          | 0/3 (0)                    |

Fig. 2. SARS-CoV-2 viral gene copy number (log copies/mL), subgenomic RNA, and virus culture as a function of days after symptom onset for patients with COVID-19. (A) N gene; (B) S gene; red dot, positive subgenomic RNA and positive virus culture; blue dot, positive subgenomic RNA and negative virus culture; green dot, negative subgenomic RNA and negative virus culture; purple triangle, positive subgenomic RNA and invalid virus culture due to contamination or cell detachment; blank triangle, negative subgenomic RNA and invalid virus culture due to contamination or cell detachment.
indicated the decreasing ratio from specimens in patients with the late course of COVID-19 [7]. So, it is interesting whether a certain cut-off value of the ratio of viral subgenomic RNAs to viral genomic RNAs may more exactly reflect the viable viral shedding. Further studies are needed in this area.

The detection of genomic RNA has greatly contributed for the early diagnosis of patients with SARS-CoV-2 infection. However, the genomic RNA detection that cannot differentiate viable virus from non-viable virus inevitably results in the prolonged isolation of patients with SARS-CoV-2 infection and the unnecessary quarantine of contacts with those with SARS-CoV-2 infection who have less chance to transmit the virus. The recent studies that the rapid antigen test (RAT) but not genomic RNA detection was correlated with SARS-CoV-2 viral culture [14,15]. However, many other studies raised the issues on the suboptimal sensitivity of RAT [16,17]. In this context, our findings showing that the subgenomic RNA detection had comparable sensitivity to the genomic RNA detection and higher specificity for the viable virus than the genomic RNA detection further facilitate our venture toward the transmissibility-based approach instead of the diagnosis-based approach. For example, the surveillance genomic PCR test may be positive in asymptomatic individuals. If these persons do not have any known exposure to the confirmed SARS-CoV-2 infected patients, the subgenomic RNA detection may be useful for the epidemiologic investigation and isolation policy. In addition, the subgenomic RNA detection may objectively guide the de-isolation policy for immunocompromised patients with COVID-19 or those with severe COVID-19.

Our study has some limitations. First, the subgenomic RNA PCR assay we developed was not quantitative. A quantitative assay such as real-time PCR might provide more reliable information about the presence of viable virus. We are currently developing real-time PCR assays against subgenomic RNA. Second, some may argue that the cell culture procedure that is considered the gold standard for detecting viable SARS-CoV-2 is not so sensitive that underestimation of viable virus is possible. Therefore, a clinical parameter such as symptom duration might be more valuable; hence recent guidelines have symptom cessation as the indicator for discontinuing transmission-based precautions. We therefore analysed positivity for subgenomic RNA, genomic RNA and cell culture as a function of time of symptom onset (Table 3 and Table S4). However, it is difficult to estimate the time of symptom onset in some patients due to pauci- or null symptoms. Thus, our evidence that detection of subgenomic RNA is closely correlated with symptom duration may facilitate objective test-based discontinuation of precautions. Finally, we did not evaluate the diagnostic performance of various genetic variants including alpha-, beta-, gamma- and delta-variants because there were limited reported cases in South Korea during the study period.

In conclusion, this study shows that subgenomic RNA was detected for a few days after viral culture turns negative, but the mean duration of viral shedding assessed by subgenomic RNA detection was much more similar to that of virus culture in moderate-to-critical patients than that assessed by detecting genomic RNA. Therefore, subgenomic RNA could be a useful surrogate for predicting the duration of infectious viral shedding.

Transparency declaration

None. This study was supported by grants from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), which is funded by the Ministry of Health & Welfare, Republic of Korea (grant No. HW20C2062) and from the National Research Foundation of Korea (NRF) funded by the Ministry of Science and ICT, Republic of Korea (NRF-2018M3A9H405637).

Author contributions

Writing — Original Draft: J.Y.K, S.B. and S.H.K.; Writing — Review and Editing: J.Y.K., S.B., S.H.K. and M.S.P.; Conceptualization: S.H.K., J.J., M.J.K. and M.S.P.; Investigation: J.Y.K., J.Y.B., H.H.C., J.S.K., C.C., H.P. and J.L.; Resources: S.B., M.H.S. and H.J.L.; Methodology: J.Y.K.; Data curation: J.Y.K., M.J.K., M.H.S. and H.J.L.; Formal Analysis: J.Y.K., H.H.C. and J.S.K. All authors critically revised the manuscript for important intellectual content.

Acknowledgement

We thank Sung-Cheol Yun, PhD, who is a professor of Clinical Epidemiology and Biostatistics, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, for his assistance with the statistical analysis.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.cmi.2021.08.009.

References

[1] To KK, Tsang OT, Leung WS, Tam AR, Wu TC, Lung DC, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis 2020;20:565–74.
[2] Xiao AT, Tong YX, Cao C, Zhu L, Zhang YJ, Zhang S. Dynamic profile of RT-PCR findings from 301 COVID-19 patients in Wuhan, China: a descriptive study. J Clin Virol 2020;127:104346.
[3] Sawicki SG, Sawicki DL, Siddell SG. A contemporary view of coronavirus transcription. J Virol 2007;81:20–9.
[4] Sola I, Almajan F, Zuniga S, Enjuanes L. Continuous and discontinuous RNA synthesis in coronaviruses. Annu Rev Virol 2015;2:265–88.
[5] Snijder EJ, Limpens RWAL, de Wilde AH, de Jong AWM, Zevenhoven-Dobbe JC, Maer HJ, et al. A unifying structural and functional model of the coronavirus replication organelle: tracking down RNA synthesis. PLoS Biol 2020;18:e3000715.
[6] Pereira R, Tso E, Tsang O, Tsang DNC, Fung K, Leung WYY, et al. SARS-CoV-2 virus culture and subgenomic RNA for respiratory specimens from patients with mild coronavirus disease. Emerg Infect Dis 2020;26:2701–4.
[7] Wolff R, Corman VM, Guggemos W, Seilmaier M, Zange S, Muller MA, et al. Virological assessment of hospitalized patients with COVID-2019. Nature 2020;581:465–9.
[8] Alexanderson S, Channings A, Bhatta TR. SARS-CoV-2 genomic and subgenomic RNAs in diagnostic samples are not an indicator of active replication. Nat Commun 2020;11:6099.
[9] Huang JT, Ran RX, Lv ZH, Feng LN, Ran CY, Tong YQ, et al. Chronological changes of viral shedding in adult inpatients with COVID-19 in Wuhan, China. Clin Infect Dis 2020;71:2158–66.
[10] Han J, Shi LX, Xie Y, Zhang YJ, Huang SP, Li JG, et al. Analysis of factors affecting the prognosis of COVID-19 patients and viral shedding duration. Epidemiol Infect 2020;148:e125.
[11] Sun J, Xiao J, Sun R, Tang X, Liang C, Lin H, et al. Prolonged persistence of SARS-CoV-2 RNA in body fluids. Emerg Infect Dis 2020;26:1834–8.
[12] Van Kampen Jja, van de Vijver DAMC, Fraaij PLA, Haagmans BL, Lamers MM, Oubaa N, et al. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19). Nat Commun 2021;12:267.
[13] Kim MC, Cui C, Shin KR, Bae JY, Kweon OJ, Lee MK, et al. Duration of culturable SARS-CoV-2 in hospitalized patients with covid-19. N Engl J Med 2021;384:671–3.
[14] Pekosz A, Parvu V, Li M, Andrews JC, Manabe YC, Kodsi S, et al. Antigen-based testing but not real-time polymerase chain reaction correlates with severe acute respiratory syndrome coronavirus 2 viral culture. Clin Infect Dis 2021;73(9):e2861–6. https://doi.org/10.1093/cia/ciaa1706.
[15] Prince-Quera J, Almendares D, Nolen LD, Gunn JK, Dale AP, Bueno SA, et al. Evaluation of Abbott BinaxNOW rapid antigen test for SARS-CoV-2 infection at...
two community-based testing sites — pima County, Arizona, November 3-17, 2020. MMWR Morb Mortal Wkly Rep 2021;70:100–5.

[16] Oh SM, Jeong H, Chang E, Choe PG, Kang CK, Park WB, et al. Clinical application of the standard Q COVID-19 Ag test for the detection of SARS-CoV-2 infection. J Korean Med Sci 2021;36:e101.

[17] Mack CD, Osterholm M, Wasserman EB, Petruski-Ivleva N, Anderson DJ, Myers E, et al. Optimizing SARS-CoV-2 surveillance in the United States: insights from the national football league occupational health program. Ann Intern Med 2021;174:1081–9.